Citation Impact
Citing Papers
Humanized Foxp2 accelerates learning by enhancing transitions from declarative to procedural performance
2014 StandoutNobel
The 2.6 Angstrom Crystal Structure of a Human A 2A Adenosine Receptor Bound to an Antagonist
2008 StandoutScience
Cancer Invasion and the Microenvironment: Plasticity and Reciprocity
2011 Standout
Molecular mechanisms of L-DOPA-induced dyskinesia
2008
Adenosine receptors and Huntington's disease: implications for pathogenesis and therapeutics
2003
Syndemics and the biosocial conception of health
2017 Standout
The influence of intracellular calcium concentration on degranulation of dialysed mast cells from rat peritoneum.
1988 StandoutNobel
Adenosine A2A Receptor Antagonists for Parkinson???s Disease
2005
Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease
2005
Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease
2002
Calcium's Role in Mechanotransduction during Muscle Development
2014 Standout
Adenosine receptors in the nervous system: pathophysiological implications
2002
The role of autophagy in neurodegenerative disease
2013 Standout
Contributions of Receptor Desensitization and Saturation to Plasticity at the Retinogeniculate Synapse
2002
NMDA Receptor Subunits Have Differential Roles in Mediating Excitotoxic Neuronal Death BothIn VitroandIn Vivo
2007
Pre-Evaluated Safe Human iPSC-Derived Neural Stem Cells Promote Functional Recovery after Spinal Cord Injury in Common Marmoset without Tumorigenicity
2012 StandoutNobel
Ligand-regulated oligomerization of β2-adrenoceptors in a model lipid bilayer
2009 StandoutNobel
Motor stimulant effects of the adenosine A2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats
2001
Staging of brain pathology related to sporadic Parkinson’s disease
2002 Standout
New therapies for the treatment of Parkinson's disease: Adenosine A2A receptor antagonists
2005
Effects of the substituted (S)-3-phenylpiperidine (−)-OSU6162 on PET measurements of [11C]SCH23390 and [11C]raclopride binding in primate brains
1999 StandoutNobel
Lack of tolerance to motor stimulant effects of a selective adenosine A2A receptor antagonist
2000
Differential regulation of microglial motility by ATP/ADP and adenosine
2009
The adolescent brain and age-related behavioral manifestations
2000 Standout
Allosteric modulators of NR2B‐containing NMDA receptors: molecular mechanisms and therapeutic potential
2009
Dopamine Receptor Subtype Agonists and Feeding Behavior
1995
Adenosine, neurodegeneration and neuroprotection
2005
Parkinson's disease
2009 Standout
Therapeutic potential of adenosine A2A receptor antagonists in Parkinson's disease
2004
Gradual and stepwise changes in the membrane capacitance of rat peritoneal mast cells.
1987 StandoutNobel
TREM2 Lipid Sensing Sustains the Microglial Response in an Alzheimer’s Disease Model
2015 Standout
Decoding ALS: from genes to mechanism
2016 StandoutNature
Ca2+ binding kinetics of fura-2 and azo-1 from temperature-jump relaxation measurements
1988 StandoutNobel
Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson’s Disease
2016 Standout
Shedding light on the cell biology of extracellular vesicles
2018 Standout
Parkinson's disease
2015 Standout
Homeostatic plasticity in the developing nervous system
2004 Standout
Mechanisms underlying NMDA receptor synaptic/extrasynaptic distribution and function
2011
Copper-Zinc Superoxide Dismutase (SOD1) Is Released by Microglial Cells and Confers Neuroprotection against 6-OHDA Neurotoxicity
2012 Standout
Novel pharmacological targets for the treatment of Parkinson's disease
2006
Physiology and Pathophysiology of Purinergic Neurotransmission
2007 Standout
Placebo response in Parkinson's disease: Comparisons among 11 trials covering medical and surgical interventions
2008
Adult Neurogenesis in the Mammalian Brain: Significant Answers and Significant Questions
2011 Standout
Stimulation of the D5 dopamine receptor acidifies the lysosomal pH of retinal pigmented epithelial cells and decreases accumulation of autofluorescent photoreceptor debris
2012
Decreased adenosine receptor binding in dystonic brains of the dtsz mutant
2005
Establishment of graded spinal cord injury model in a nonhuman primate: The common marmoset
2005
A dual-Ca2+-sensor model for neurotransmitter release in a central synapse
2007 StandoutNatureNobel
New Aspects of Physiological and Pathophysiological Functions of Adenosine A2AReceptor in Basal Ganglia
2001
Distribution, biochemistry and function of striatal adenosine A2A receptors
1999
Microglia Promote Learning-Dependent Synapse Formation through Brain-Derived Neurotrophic Factor
2013 Standout
A Critical Interaction between NR2B and MAGUK in l-DOPA Induced Dyskinesia
2006
Cross-talk between calcium and cAMP-dependent intracellular signaling pathways. Implications for synergistic secretion in T84 colonic epithelial cells and rat pancreatic acinar cells.
1995 StandoutNobel
Contrasting effects of excitotoxic lesions of the prefrontal cortex on the behavioural response to d-amphetamine and presynaptic and postsynaptic measures of striatal dopamine function in monkeys
1997
Blockade of adenosine A2A receptors antagonizes parkinsonian tremor in the rat tacrine model by an action on specific striatal regions
2004
Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias
2004
Effects of SCH 58261, an Adenosine A2A Receptor Antagonist, on Quinpirole-Induced Turning in 6-Hydroxydopamine-Lesioned Rats Lack of Tolerance after Chronic Caffeine Intake
2000
Second messenger‐activated calcium influx in rat peritoneal mast cells.
1989 StandoutNobel
Adenosine receptors and l-DOPA-induced dyskinesia in Parkinson's disease: potential targets for a new therapeutic approach
2003
Targeting adenosine A2A receptors in Parkinson's disease
2006
Sleepiness and unintended sleep in Parkinson’s disease
2003
NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease
2013 Standout
Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer
2008
Dopamine, learning and motivation
2004 Standout
Microglia Sculpt Postnatal Neural Circuits in an Activity and Complement-Dependent Manner
2012 Standout
Novel nondopaminergic targets for motor features of Parkinson's disease: Review of recent trials
2012
The MPTP-treated primate as a model of motor complications in PD
2003
Control of cytoplasmic calcium with photolabile tetracarboxylate 2-nitrobenzhydrol chelators
1986 StandoutNobel
Adenosine Receptor Antagonists: Translating Medicinal Chemistry and Pharmacology into Clinical Utility
2008
The effect of the adenosine A2A antagonist KW-6002 on motor and motivational processes in the rat
2005
Dopaminergic Modulation of NMDA-Induced Whole Cell Currents in Neostriatal Neurons in Slices: Contribution of Calcium Conductances
1998
ACTIONS OF ADENOSINE AT ITS RECEPTORS IN THE CNS: Insights from Knockouts and Drugs
2004
Homologous Desensitization of the D1A Dopamine Receptor: Efficacy in Causing Desensitization Dissociates from Both Receptor Occupancy and Functional Potency
1998
Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease.
2001
Intensely pleasurable responses to music correlate with activity in brain regions implicated in reward and emotion
2001 Standout
Spatial distribution of calcium channels and cytosolic calcium transients in growth cones and cell bodies of sympathetic neurons.
1988 StandoutNobel
ABCs (and Ds) of Understanding VARs
2007 StandoutNobel
Chromone: A Valid Scaffold in Medicinal Chemistry
2014 Standout
A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease
2008
Linear-Quadratic Approximation and Value-Function Iteration: A Comparison
1990
Activation of a potassium current by rapid photochemically generated step increases of intracellular calcium in rat sympathetic neurons.
1987 StandoutNobel
Regulation of the mannose 6-phosphate/IGF II receptor expression at the cell surface by mannose 6-phosphate, insulin like growth factors and epidermal growth factor.
1989 StandoutNobel
Fluorescent Sensors for Measuring Metal Ions in Living Systems
2014 Standout
The 5HT2 receptor defines a family of structurally distinct but functionally conserved serotonin receptors.
1990 StandoutNobel
Dementia with Lewy bodies.
2004
β-Arrestin-biased ligands at seven-transmembrane receptors
2007 StandoutNobel
Sequential activation and lethal hit measured by [Ca2+]i in individual cytolytic T cells and targets.
1987 StandoutNobel
Rat brain serotonin receptors in Xenopus oocytes are coupled by intracellular calcium to endogenous channels.
1987 StandoutNobel
Regulation of the phosphorylation of the dopamine- and cAMP-regulated phosphoprotein of 32 kDa in vivo by dopamine D 1 , dopamine D 2 , and adenosine A 2A receptors
2000
Thapsigargin, a tumor promoter, discharges intracellular Ca2+ stores by specific inhibition of the endoplasmic reticulum Ca2(+)-ATPase.
1990 Standout
Fast calcium transients in rat peritoneal mast cells are not sufficient to trigger exocytosis.
1986 StandoutNobel
International Union of Pharmacology. XXV. Nomenclature and Classification of Adenosine Receptors
2001 Standout
Crosslinkage of B lymphocyte surface immunoglobulin by anti-Ig or antigen induces prolonged oscillation of intracellular ionized calcium.
1987 StandoutNobel
Chemotherapy triggers HIF-1–dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype
2015 StandoutNobel
Dopamine D 1 and adenosine A 1 receptors form functionally interacting heteromeric complexes
2000
Physiology of Microglia
2011 Standout
Works of Lance A. Smith being referenced
Dopamine, but Not Norepinephrine or Serotonin, Reuptake Inhibition Reverses Motor Deficits in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Treated Primates
2002
Biphenyl-derivatives of 2-amino-7-phosphono-heptanoic acid, a novel class of potent competitive N-Methyl-D-aspartate receptor antagonists—II. Pharmacological characterization in vivo
1996
Combined Use of the Adenosine A2A Antagonist KW-6002 with l-DOPA or with Selective D1 or D2 Dopamine Agonists Increases Antiparkinsonian Activity but Not Dyskinesia in MPTP-Treated Monkeys
2000
Switching from Levodopa to the Long-acting Dopamine D2/D3 Agonist Piribedil Reduces the Expression of Dyskinesia While Maintaining Effective Motor Activity in MPTP-treated Primates
2006
A-77636: a potent and selective dopamine D1 receptor agonist with antiparkinsonian activity in marmosets
1992
Effect of pulsatile administration of levodopa on dyskinesia induction in drug‐naïve MPTP‐treated common marmosets: Effect of dose, frequency of administration, and brain exposure
2003
Repeated administration of piribedil induces less dyskinesia than L ‐dopa in MPTP‐treated common marmosets: A behavioural and biochemical investigation
2002
Beginning‐of‐dose and rebound worsening in MPTP‐treated common marmosets treated with levodopa
2002
Osteopontin expression in substantia nigra in MPTP-treated primates and in Parkinson's disease
2006
Adenosine A2A Antagonist: A novel antiparkinsonian agent that does not provoke dyskinesia in Parkinsonian monkeys
1998
Antiparkinsonian activity of Ro 25-6981, a NR2B subunit specific NMDA receptor antagonist, in animal models of Parkinson's disease
2004
Decreased expression of l-dopa-induced dyskinesia by switching to ropinirole in MPTP-treated common marmosets
2006
The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of l-DOPA in MPTP treated common marmosets
2006
Alterations in striatal and extrastriatal D‐1 and D‐2 dopamine receptors in the MPTP‐treated common marmoset: An autoradiographic study
1993
On the superneutrality of money in a stochastic dynamic macroeconomic model
1987
Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP‐treated drug‐naïve primates
2005
3,4-Methylenedioxymethamphetamine (Ecstasy) Inhibits Dyskinesia Expression and Normalizes Motor Activity in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Treated Primates
2003